GHK-Cu in the research record: doses, routes, half-life, and stability

GHK-Cu research doses across models

GHK-Cu research doses span six orders of magnitude because the compound has been studied from single cells to whole animals, and this brief reports each as a study parameter rather than a recommendation. In vitro, fibroblast collagen synthesis is driven at 10^-12 to 10^-9 M, with onset between 10^-12 and 10^-11 M and a peak near 10^-9 M ^[1]. Topical cosmetic and clinical formulations are studied at roughly 0.05% to 2% (w/w) in creams, serums, and gels ^[6].

In rodent systemic work, intraperitoneal doses have ranged from 0.2 to 20 ug/g/day in a pulmonary-emphysema model up to 2 and 20 mg/kg in a silicosis model, while DSS-colitis used 20 mg/kg by oral gavage daily ^[6]. The cognition studies used 15 mg/kg intranasally, either daily or three times weekly ^[8][9]. The one human-trial figure is topical: the ALAVAX 5-ALA+GHK hair complex at 50 to 100 mg/mL ^[4]. None of these is a human dose recommendation; they are the conditions under which effects were observed in the cited species and models.

Half-life and pharmacokinetics: what is and isn't known

No rigorous human pharmacokinetic half-life has been published for GHK-Cu ^[6]. The free tripeptide (340.38 Da) is rapidly cleared by plasma peptidases: a rat HPLC study documented rapid metabolism of GHK to the dipeptide histidyl-lysine (HK) after intravenous dosing, with detection limits of 50 ng/mL for GHK and 15 ng/mL for HK ^[14]. Secondary literature cites a short systemic elimination half-life on the order of 1 to 2 hours, with the copper-chelated complex being more stable than free GHK ^[6].

Topical application behaves differently because it builds a reservoir rather than a plasma peak. A human penetration study found that about 97 ug/cm^2 of copper was retained as a dermal depot over 48 hours, giving prolonged local availability even as systemic clearance of the free peptide stays fast ^[5]. The honest summary: local topical kinetics are partly characterized; systemic human kinetics are not.

Routes studied and formulation stability

The routes in the literature are topical (cream, serum, liposome, nano-lipid carrier, ionic-liquid microemulsion, wound dressing, hydrogel, nanofiber), intraperitoneal (rodent systemic studies), intranasal (rodent cognition), oral gavage (rodent colitis), intravenous and subcutaneous (rodent pharmacokinetics), and intradermal or dermal infusion via microneedle in hair studies ^[6][8]. The breadth reflects the central delivery problem: free GHK is highly hydrophilic (clogP -2.24) and crosses skin poorly, so formulation work has dominated recent literature ^[11].

Stability is governed by the copper chelate. The GHK-Cu complex has a very high copper stability constant (log K about 16.4), far higher than free GHK, which limits pro-oxidant free-copper release ^[6]. It is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio; the blue-violet color of a reconstituted solution is the expected copper(II) absorption and indicates an intact complex, whereas a brown or green shift indicates oxidation or precipitation ^[6]. Strong reducing agents — ascorbic acid below about pH 3.5 — reduce the copper(II) and break the complex ^[6].

Why the route changes the dose so dramatically

The six-orders-of-magnitude spread above is not noise; it is a direct consequence of the delivery barrier and the pharmacokinetics. In cell culture there is no barrier and no clearance, so the peptide acts at picomolar-to-nanomolar concentrations — the onset for collagen synthesis is 10^-12 to 10^-11 M, with a peak near 10^-9 M ^[1]. The moment a study moves into a whole animal, it must overcome rapid plasma peptidase clearance of the free peptide and, for any tissue target, a permeability barrier — which is why systemic rodent work uses milligram-per-kilogram doses ^[6][14].

The intranasal cognition studies are the clearest illustration. By delivering 15 mg/kg through the nose-to-brain pathway rather than systemically, those studies reached CNS tissue without relying on blood-brain-barrier crossing or on surviving plasma clearance ^[8][9]. Topical dermatology takes the opposite tack: it accepts that little reaches the circulation and instead builds a dermal copper depot — about 97 ug/cm^2 retained over 48 hours — where the peptide can act locally and persistently ^[5]. Reading any GHK-Cu dose figure therefore means reading the route alongside it; a nanomolar culture concentration, a 15 mg/kg intranasal dose, and a 50 mg/mL topical complex are not three points on one scale but three different experiments answering three different questions ^[1][8][4].

Reading dose figures responsibly

Every dose on this page is reported as it appeared in a cited study, attached to a species and a route, and none of it is a recommendation for a person. The compound has no FDA- or EMA-approved therapeutic indication by any route, and there is no validated human pharmacokinetic dataset — no published human half-life, Cmax, bioavailability, or tissue-distribution figures for injectable or systemic GHK-Cu ^[6]. Injectable and systemic dosing protocols that circulate in community contexts have no peer-reviewed basis ^[6].

The firmest human number in the entire record is a topical one — the 50 to 100 mg/mL ALAVAX 5-ALA+GHK hair complex used over six months — and even that tested a combination formula rather than pure GHK-Cu ^[4]. The small placebo-controlled facial trials (roughly n=20 to 71 subjects) report topical concentrations and outcomes but do not establish systemic dosing, and the one registered topical wound-healing trial (CuHeal, NCT07437586) is likewise topical ^[6]. The pattern across the human record is consistent: where doses are documented, they are surface doses, measured locally.

Readers weighing what the numbers mean will find the most-asked points collected in the common questions about GHK-Cu, where the safety, formulation, and timeline questions are answered against the same studies cited here. The single rule this brief applies throughout is the one the compliance literature insists on: describe what was studied at what dose in which species or model, and never translate that into guidance for a person ^[6].